Catalyst Crew Technologies Corp. (OTC: CCTC) announced the ongoing development of CardioAI, an artificial intelligence-enabled module designed to support cardiovascular risk assessment and predictive modeling for healthcare providers. The platform is intended to analyze cardiovascular health data and identify potential clinical risks using AI-driven analytics, with proposed capabilities including heart failure risk modeling, arrhythmia detection, coronary artery disease risk scoring, and AI-assisted analysis of electrocardiograms (ECG) and echocardiograms (ECHO).
CardioAI is being developed to integrate multiple data inputs such as diagnostic imaging, clinical parameters, laboratory results, and patient demographic information to generate structured outputs for clinical review and care coordination. The platform forms part of the Company’s broader AI healthcare ecosystem and is expected to function as a specialized module within Catalyst Crew’s digital health platform. Management believes modular AI systems like CardioAI can support scalable deployment across telehealth services, remote patient monitoring, and technology-enabled healthcare delivery.
The Company intends to integrate CardioAI across its existing and planned healthcare infrastructure initiatives, including its healthcare services coordination platform. As development progresses, CardioAI is being designed to support data-driven insights and clinical decision-support capabilities across multiple points of care. Catalyst Crew Technologies is prioritizing market development in Latin America, where AI-enabled healthcare technologies may help expand access to cardiovascular screening, support early risk identification, and improve healthcare system efficiency. The region represents a significant opportunity for digital health innovation as healthcare systems seek scalable solutions to improve diagnostic capabilities and support remote patient care.
Dr. Kevin Rodan Levy, Chief Executive Officer of Catalyst Crew Technologies Corp., stated: “Cardiovascular disease remains one of the leading global health challenges, and we believe artificial intelligence can play an important role in supporting earlier detection and more informed clinical decision-making. CardioAI reflects our broader strategy of developing modular, scalable healthcare technologies designed to integrate into real-world healthcare delivery systems.”
The Company intends to continue developing and refining CardioAI and its broader healthcare technology platform while evaluating opportunities for pilot programs, strategic partnerships, and phased market deployment. For more information, visit https://catalystcrewai.com or review the Company’s filings with the SEC at www.sec.gov.
This press release contains forward-looking statements regarding the Company’s business strategy, leadership initiatives, strategic transactions, operational execution, and regulatory matters. Actual results may differ materially due to risks including the Company’s ability to implement its business plan, secure financing, complete acquisitions, comply with regulatory requirements, and general market conditions. The Company undertakes no obligation to update forward-looking statements except as required by law. This press release is for informational purposes only and does not constitute an offer to sell securities.
